Lv11
10 积分 2021-09-20 加入
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
8小时前
待确认
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
2个月前
已完结
Efficacy of dual KRASG12D–EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer
2个月前
已完结
The evolving landscape of RAS-targeted therapies
2个月前
已完结
Glue-based KRAS inhibitors make their debut cancer trial mark
2个月前
已完结
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
2个月前
已完结
Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes
4个月前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
7个月前
已完结
Combined peritoneal and liver metastases in colorectal cancer: A Dutch nationwide population-based analysis of incidence, treatment and survival
8个月前
已完结
皖公网安备34019202002308
